ClinicalTrials.gg
CompletedNCT00652626RENALUpdated Nov 19, 2019Results posted

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

A Phase 1 interventional study of azacitidine in MDS, AML and Solid Tumors, sponsored by Celgene. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing azacitidine in Multiple Myeloma — none open to participants now, 1 under way, none of them phase 3. Azacitidine · Multiple Myeloma.

Started
2008
with 1 other
Phase 1
4 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
3 of 10
Celgene

Among the 10 studies testing azacitidine in Multiple Myeloma, this one is one of 2 that started in 2008, is one of 4 in phase 1, and was the 3rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 10 studies testing azacitidine in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →

Where they have run

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing azacitidine in Multiple Myeloma as a file.
02

Study summary

The purpose of this study is to evaluate three things. The first being whether azacitidine is absorbed in the body at the same rate or proportion for different concentrations. The second is to determine the effect renal impairment has or does not have on the absorption of azacitidine. The third is to determine if azacitidine is safe and well tolerated in patients with renal function impairment.

03

Conditions studied

  • MDS
  • AML
  • Solid Tumors
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Disease

Keywords

  • MDS
  • AML
  • Solid Tumors
  • Azacitidine
  • PK
  • Pharmacokinetics
  • Renal Impairment
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of one of the following:

    • MDS according to the French-American-British (FAB) classification system: anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), or chronic myelomonocytic leukemia (CMML); or
    • Acute myelogenous leukemia (AML) in remission,
    • Malignant solid tumor,
    • Multiple myeloma (MM),
    • Non-Hodgkin lymphoma (NHL), or
    • Hodgkin lymphoma (HD)
  • Patients with a history of treated should be clinically stable for greater than 4 weeks prior to signing the form and off therapy for central nervous system (CNS) edema for at least 4 weeks
  • Be capable of giving informed consent
  • Have an (ECOG) performance status of 0-2
  • Have a ≥ 3 months
  • Have stable renal function for at least 2 months
  • Have average calculated of:

    • >80 mL/min/1.73m\^2 for Cohorts 1, 2, 3, and 4
    • \<30 mL/min/1.73m\^2 for Cohort 5 - Severe renal impairment,
    • 50-80 mL/min/1.73m\^2 for Cohort 6 - Mild renal impairment,
    • 30 to \<50 mL/min/1.73m\^2 for Cohort 7 - Moderate renal impairment
  • Have organ and marrow function at the screening and pre-dose visits as defined below:

    • ≥8 g/dL,
    • ≥0.75 x 10\^3/µL,
    • ≥30 x 10\^3/µL,
    • Total ≤1.5 times the (ULN),
    • (AST) ≤2 times the ULN, and
    • Alanine transaminase (ALT) ≤2 times the ULN;
  • Have a 12-lead (ECG) that is not , as determined by the Investigator, at screening
  • Have serum bicarbonate:

    • 20 mEq/L for patients with normal renal function (cohorts 1, 2, 3 and 4),
    • 16 mEq/L for patients with impaired renal function (cohorts 5, 6 and 7)
  • Women of may participate, providing are not pregnant and agree to use at least 2 effective methods throughout the study
  • Males with a female partner of childbearing potential must agree to use at least 2 effective contraceptive methods throughout the study and to avoid fathering a child for 6 months following the date of the last dose of study medication
  • Be a nonsmoker or must not have smoked for at least 30 days before the screening visit and agree to abstain from smoking during study participation

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or nursing;
  • Had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to signing
  • Have been treated with an agent within 4 weeks prior to signing the informed consent form
  • Have ongoing adverse event(s) due to chemotherapy, radiotherapy or investigational agents administered more than 4 weeks prior to signing the informed consent as determined by the Investigator
  • Have known or suspected to azacitidine or mannitol
  • Have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
  • Have low blood pressure (supine blood pressure \<90/60 mmHg)
  • Have (HIV), or active hepatitis virus B or C
  • Have advanced malignant hepatic tumors
  • Have end stage renal disease requiring dialysis
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Azacitidine 25 mg/m^2

    Participants with normal renal function received a single subcutaneous dose of azacitidine 25 mg/m\^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.

    Drug: azacitidine

  • Experimental
    Azacitidine 50 mg/m^2

    Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m\^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.

    Drug: azacitidine

  • Experimental
    Azacitidine 75 mg/m^2

    Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.

    Drug: azacitidine

  • Experimental
    Azacitidine 100 mg/m^2

    Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m\^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.

    Drug: azacitidine

  • Experimental
    Severe RI: azacitidine 75 mg/m^2

    Participants with severe renal impairment (RI; defined as creatinine clearance \< 30 mL/min/1.73 m\^2) received subcutaneous doses of azacitidine 75 mg/m\^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m\^2 daily on Days 1-7 of each 28-day cycle.

    Drug: azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose

    Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of azacitidine following a single dose of azacitidine on Day 1, calculated by the linear trapezoidal rule.

    Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  2. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point

    Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of azacitidine following a single dose of azacitidine on Day 1, calculated by the linear trapezoidal rule.

    Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  3. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity

    The area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) for azacitidine after a single dose, calculated by the linear trapezoidal rule and extrapolated to infinity according to the following equation: AUC0-inf = AUC0-t + (Ct/ke), where Ct is the last quantifiable concentration and ke = elimination rate constant.

    Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  4. Maximum Plasma Concentration of Azacitidine (Cmax)

    The maximum observed plasma concentration of azacitidine after a single dose on Day 1.

    Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  5. Time to Maximum Plasma Concentration of Azacitidine (Tmax)

    The time to first maximum observed plasma concentration of azacitidine after a single dose on Day 1.

    Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  6. Terminal Phase Half-life of Azacitidine (t½)

    The terminal phase half-life of azacitidine after a single dose on Day 1, calculated according to the following equation: t½ = 0.693/λz, where λz is the terminal phase rate constant.

    Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  7. Apparent Total Clearance of Azacitidine (CL/F)

    The apparent total clearance of azacitidine after a single dose on Day 1, calculated as Dose/AUC0-inf.

    Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  8. Apparent Volume of Distribution of Azacitidine (Vz/F)

    The apparent volume of distribution of azacitidine after a single dose on Day 1, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (λz)

    Time frame: Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  9. Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose After Single and Multiple Doses of Azacitidine

    The effect of renal impairment on azacitidine pharmacokinetics was analyzed by comparing PK parameters obtained on Days 1 and 5 from participants with severe renal impairment and those with normal renal function. Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of azacitidine following a single dose (Day 1) and multiple doses (Day 5) was calculated by the linear trapezoidal rule.

    Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  10. Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Time Point After Single and Multiple Doses of Azacitidine

    The area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of azacitidine following a single dose (Day 1) and multiple doses (Day 5) was calculated by the linear trapezoidal rule for participants with normal renal function and for participants with severe renal impairment.

    Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  11. Area Under the Plasma Concentration-time Curve From Time 0 to Infinity After Single and Multiple Doses of Azacitidine

    The area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) for azacitidine, after a single dose (Day 1) and multiple doses (Day 5), calculated by the linear trapezoidal rule and extrapolated to infinity according to the following equation: AUC0-inf = AUC0-t + (Ct/ke), where Ct is the last quantifiable concentration and ke = elimination rate constant.

    Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  12. Maximum Plasma Concentration of Azacitidine (Cmax) After Single and Multiple Doses of Azacitidine

    The maximum observed plasma concentration of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and for participants with severe renal impairment.

    Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  13. Time to Maximum Plasma Concentration of Azacitidine (Tmax) After Single and Multiple Doses of Azacitidine

    The time to first maximum observed plasma concentration of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and severe renal impairment.

    Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  14. Terminal Phase Half-life of Azacitidine (t½) After Single and Multiple Doses of Azacitidine

    The terminal phase half-life of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated according to the following equation: t½ = 0.693/λz, where λz is the terminal phase rate constant.

    Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  15. Apparent Total Clearance of Azacitidine (CL/F) After Single and Multiple Doses of Azacitidine

    The apparent total clearance of azacitidine after a single dose (Day 1) and multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated as Dose/AUC0-inf.

    Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  16. Apparent Volume of Distribution of Azacitidine (Vz/F) After Single and Multiple Doses of Azacitidine

    The apparent volume of distribution of azacitidine after a single dose (Day 1) and multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (λz).

    Time frame: Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose

  17. Number of Participants With Adverse Events (AEs)

    A serious adverse event is one that at any dose of the study drug or at any time during the period of observation: * Results in death; * Is life threatening; * Requires inpatient hospitalization or prolongation of existing hospitalization; * Results in persistent or significant disability/incapacity; * Is a congenital anomaly/birth defect; * Is medically important. The Investigator assessed each AE for potential causal relationship between the event and study drug. The intensity of adverse changes in physical signs or symptoms was graded from 1 to 5 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).

    Time frame: Initial treatment phase: Days 1-11 for participants who received a single dose; Days 1-29 for participants who received multiple doses. Extension treatment period: From the date of first dose until 28 days after the date of last dose (up to 7 months).

07

Results

Posted Oct 17, 2013

Participant flow

Initial Treatment Phase
Participant flow — Initial Treatment Phase
MilestoneAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RI
Started5576800
Received study drug5565600
Completed5565500
Not completed0011300
Withdrew: Adverse event0000100
Withdrew: Protocol violation0001000
Withdrew: Physician decision0000100
Withdrew: Sponsor request0010000
Withdrew: Lost to follow-up0000100
Extension Phase
Participant flow — Extension Phase
MilestoneAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RI
Started00000144
Completed0000021
Not completed00000123
Withdrew: Withdrawal by subject0000020
Withdrew: Adverse event0000021
Withdrew: No longer receiving clinical benefit0000060
Withdrew: Physician decision0000011
Withdrew: Death0000011

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose

Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of azacitidine following a single dose of azacitidine on Day 1, calculated by the linear trapezoidal rule.

Time frame:
Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose
ng*hr/mLAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2
Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose455.86 ± 26.04897.43 ± 31.00921.87 ± 39.2151502.86 ± 25.57
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point

Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of azacitidine following a single dose of azacitidine on Day 1, calculated by the linear trapezoidal rule.

Time frame:
Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point
ng*hr/mLAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Time Point454.80 ± 26.22895.38 ± 31.20920.76 ± 39.201505.16 ± 25.57
Statistical analysis
  • Azacitidine 25 mg/m^2 vs Azacitidine 50 mg/m^2 · Ratio (%) of geometric means: 98.4 · 90% CI 64.0 to 151.3Ratio of geometric means is calculated as Azacitidine 50 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
  • Azacitidine 25 mg/m^2 vs Azacitidine 75 mg/m^2 · Ratio (%) of geometric means: 67.5 · 90% CI 44.7 to 101.8Ratio of geometric means is calculated as Azacitidine 75 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
  • Azacitidine 25 mg/m^2 vs Azacitidine 100 mg/m^2 · Ratio (%) of geometric means: 82.7 · 90% CI 53.8 to 127.2Ratio of geometric means is calculated as Azacitidine 100 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity

The area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) for azacitidine after a single dose, calculated by the linear trapezoidal rule and extrapolated to infinity according to the following equation: AUC0-inf = AUC0-t + (Ct/ke), where Ct is the last quantifiable concentration and ke = elimination rate constant.

Time frame:
Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity
ng*hr/mLAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity460.47 ± 25.79897.42 ± 30.93945.50 ± 39.051533.37 ± 23.96
Statistical analysis
  • Azacitidine 25 mg/m^2 vs Azacitidine 50 mg/m^2 · Ratio (%) of geometric means: 97.4 · 90% CI 63.8 to 148.8Ratio of geometric mean is calculated as Azacitidine 50 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
  • Azacitidine 25 mg/m^2 vs Azacitidine 75 mg/m^2 · Ratio (%) of geometric means: 68.5 · 90% CI 45.7 to 102.7Ratio of geometric mean is calculated as Azacitidine 75 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
  • Azacitidine 25 mg/m^2 vs Azacitidine 100 mg/m^2 · Ratio (%) of geometric means: 83.2 · 90% CI 54.5 to 127.1Ratio of geometric mean is calculated as Azacitidine 100 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
PrimaryMaximum Plasma Concentration of Azacitidine (Cmax)

The maximum observed plasma concentration of azacitidine after a single dose on Day 1.

Time frame:
Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration of Azacitidine (Cmax)
ng/mLAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2
Maximum Plasma Concentration of Azacitidine (Cmax)293.38 ± 34.11749.04 ± 61.03745.50 ± 57.901261.96 ± 39.19
Statistical analysis
  • Azacitidine 25 mg/m^2 vs Azacitidine 50 mg/m^2 · Ratio (%) of geometric means: 127.7 · 90% CI 66.3 to 245.7Ratio of geometric means is calculated as Azacitidine 50 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
  • Azacitidine 25 mg/m^2 vs Azacitidine 75 mg/m^2 · Ratio (%) of geometric means: 84.7 · 90% CI 45.3 to 158.5Ratio of geometric means is calculated as Azacitidine 75 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
  • Azacitidine 25 mg/m^2 vs Azacitidine 100 mg/m^2 · Ratio (%) of geometric means: 107.5 · 90% CI 55.9 to 207.0Ratio of geometric means is calculated as Azacitidine 100 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
PrimaryTime to Maximum Plasma Concentration of Azacitidine (Tmax)

The time to first maximum observed plasma concentration of azacitidine after a single dose on Day 1.

Time frame:
Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Median · hours
Time to Maximum Plasma Concentration of Azacitidine (Tmax)
hoursAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2
Time to Maximum Plasma Concentration of Azacitidine (Tmax)0.25 (0.25 to 1.00)0.25 (0.25 to 0.78)0.25 (0.25 to 0.50)0.27 (0.25 to 0.75)
PrimaryTerminal Phase Half-life of Azacitidine (t½)

The terminal phase half-life of azacitidine after a single dose on Day 1, calculated according to the following equation: t½ = 0.693/λz, where λz is the terminal phase rate constant.

Time frame:
Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · hours
Terminal Phase Half-life of Azacitidine (t½)
hoursAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2
Terminal Phase Half-life of Azacitidine (t½)1.38 ± 27.310.63 ± 35.721.19 ± 102.561.03 ± 78.48
PrimaryApparent Total Clearance of Azacitidine (CL/F)

The apparent total clearance of azacitidine after a single dose on Day 1, calculated as Dose/AUC0-inf.

Time frame:
Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · liters/hour
Apparent Total Clearance of Azacitidine (CL/F)
liters/hourAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2
Apparent Total Clearance of Azacitidine (CL/F)104.58 ± 25.00105.76 ± 17.03151.55 ± 30.88106.00 ± 25.64
Statistical analysis
  • Azacitidine 25 mg/m^2 vs Azacitidine 50 mg/m^2 · Ratio (%) of geometric means: 101.1 · 90% CI 71.2 to 143.6Ratio of geometric mean is calculated as Azacitidine 50 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
  • Azacitidine 25 mg/m^2 vs Azacitidine 75 mg/m^2 · Ratio (%) of geometric means: 144.9 · 90% CI 103.6 to 202.7Ratio of geometric mean is calculated as Azacitidine 75 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
  • Azacitidine 25 mg/m^2 vs Azacitidine 100 mg/m^2 · Ratio (%) of geometric means: 101.4 · 90% CI 71.4 to 143.9Ratio of geometric mean is calculated as Azacitidine 100 mg/m\^2 / Azacitidine 25 mg/m\^2 and expressed as a percentage.
PrimaryApparent Volume of Distribution of Azacitidine (Vz/F)

The apparent volume of distribution of azacitidine after a single dose on Day 1, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (λz)

Time frame:
Day 1 at predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · liters
Apparent Volume of Distribution of Azacitidine (Vz/F)
litersAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2
Apparent Volume of Distribution of Azacitidine (Vz/F)208.69 ± 45.5796.74 ± 36.75259.44 ± 121.71456.69 ± 99.41
PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose After Single and Multiple Doses of Azacitidine

The effect of renal impairment on azacitidine pharmacokinetics was analyzed by comparing PK parameters obtained on Days 1 and 5 from participants with severe renal impairment and those with normal renal function. Area under the plasma concentration-time curve from time 0 to 8 hours post-dose (AUC0-8) of azacitidine following a single dose (Day 1) and multiple doses (Day 5) was calculated by the linear trapezoidal rule.

Time frame:
Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Curve From Time 0 to 8 Hours Post-dose After Single and Multiple Doses of Azacitidine
ng*hr/mLNormal RF: Azacitidine 75 mg/m^2Severe RI: Azacitidine 75 mg/m^2
Day 1921.87 ± 39.151558.32 ± 64.95
Day 5843.03 ± 12.001183.61 ± 51.92
PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Time Point After Single and Multiple Doses of Azacitidine

The area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-t) of azacitidine following a single dose (Day 1) and multiple doses (Day 5) was calculated by the linear trapezoidal rule for participants with normal renal function and for participants with severe renal impairment.

Time frame:
Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Time Point After Single and Multiple Doses of Azacitidine
ng*hr/mLNormal RF: Azacitidine 75 mg/m^2Severe RI: Azacitidine 75 mg/m^2
Day 1920.76 ± 39.201558.72 ± 65.02
Day 5841.62 ± 11.831181.83 ± 51.98
Statistical analysis
  • Normal RF: Azacitidine 75 mg/m^2 vs Severe RI: Azacitidine 75 mg/m^2 · Ratio (%) of geometric means: 169.3 · 90% CI 109.2 to 262.5Ratio of geometric mean is calculated as Severe RI/Normal RF and expressed as a percentage.
  • Normal RF: Azacitidine 75 mg/m^2 vs Severe RI: Azacitidine 75 mg/m^2 · Ratio (%) of geometric means: 140.4 · 90% CI 90.6 to 217.7Ratio of geometric mean is calculated as Severe RI/Normal RF and expressed as a percentage.
PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to Infinity After Single and Multiple Doses of Azacitidine

The area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) for azacitidine, after a single dose (Day 1) and multiple doses (Day 5), calculated by the linear trapezoidal rule and extrapolated to infinity according to the following equation: AUC0-inf = AUC0-t + (Ct/ke), where Ct is the last quantifiable concentration and ke = elimination rate constant.

Time frame:
Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity After Single and Multiple Doses of Azacitidine
ng*hr/mLNormal RF: Azacitidine 75 mg/m^2Severe RI: Azacitidine 75 mg/m^2
Day 1946.22 ± 39.051573.82 ± 63.46
Day 5857.64 ± 9.941210.92 ± 49.07
Statistical analysis
  • Normal RF: Azacitidine 75 mg/m^2 vs Severe RI: Azacitidine 75 mg/m^2 · Ratio (%) of geometric means: 166.3 · 90% CI 108.6 to 254.6Ratio of geometric mean is calculated as Severe RI/Normal RF and expressed as a percentage.
  • Normal RF: Azacitidine 75 mg/m^2 vs Severe RI: Azacitidine 75 mg/m^2 · Ratio (%) of geometric means: 141.2 · 90% CI 92.2 to 216.2Ratio of geometric mean is calculated as Severe RI/Normal RF and expressed as a percentage.
PrimaryMaximum Plasma Concentration of Azacitidine (Cmax) After Single and Multiple Doses of Azacitidine

The maximum observed plasma concentration of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and for participants with severe renal impairment.

Time frame:
Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration of Azacitidine (Cmax) After Single and Multiple Doses of Azacitidine
ng/mLNormal RF: Azacitidine 75 mg/m^2Severe RI: Azacitidine 75 mg/m^2
Day 1745.50 ± 57.901056.66 ± 93.01
Day 5632.56 ± 45.86668.11 ± 91.64
Statistical analysis
  • Normal RF: Azacitidine 75 mg/m^2 vs Severe RI: Azacitidine 75 mg/m^2 · Ratio (%) of geometric means: 141.7 · 90% CI 73.2 to 274.6Ratio of geometric mean is calculated as Severe RI/Normal RF and expressed as a percentage.
  • Normal RF: Azacitidine 75 mg/m^2 vs Severe RI: Azacitidine 75 mg/m^2 · Ratio (%) of geometric means: 105.6 · 90% CI 54.5 to 204.6Ratio of geometric mean is calculated as Severe RI/Normal RF and expressed as a percentage.
PrimaryTime to Maximum Plasma Concentration of Azacitidine (Tmax) After Single and Multiple Doses of Azacitidine

The time to first maximum observed plasma concentration of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and severe renal impairment.

Time frame:
Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Median · hours
Time to Maximum Plasma Concentration of Azacitidine (Tmax) After Single and Multiple Doses of Azacitidine
hoursNormal RF: Azacitidine 75 mg/m^2Severe RI: Azacitidine 75 mg/m^2
Day 10.25 (0.25 to 0.50)0.50 (0.25 to 1.50)
Day 50.38 (0.25 to 0.50)0.64 (0.25 to 1.03)
Statistical analysis
  • Normal RF: Azacitidine 75 mg/m^2 vs Severe RI: Azacitidine 75 mg/m^2 · Wilcoxon (Mann-Whitney) · p = 0.1342 · Median difference (final values): 0.25 · 90% CI 0 to 0.52Median difference is Severe RI - Normal RF.
  • Normal RF: Azacitidine 75 mg/m^2 vs Severe RI: Azacitidine 75 mg/m^2 · Wilcoxon (Mann-Whitney) · p = 0.1017 · Median difference (final values): 0.25 · 90% CI 0 to 0.50Median difference is Severe RI - Normal RF.
PrimaryTerminal Phase Half-life of Azacitidine (t½) After Single and Multiple Doses of Azacitidine

The terminal phase half-life of azacitidine after a single dose (Day 1) or multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated according to the following equation: t½ = 0.693/λz, where λz is the terminal phase rate constant.

Time frame:
Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · hours
Terminal Phase Half-life of Azacitidine (t½) After Single and Multiple Doses of Azacitidine
hoursNormal RF: Azacitidine 75 mg/m^2Severe RI: Azacitidine 75 mg/m^2
Day 11.19 ± 102.560.97 ± 43.88
Day 51.03 ± 76.951.15 ± 53.86
PrimaryApparent Total Clearance of Azacitidine (CL/F) After Single and Multiple Doses of Azacitidine

The apparent total clearance of azacitidine after a single dose (Day 1) and multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated as Dose/AUC0-inf.

Time frame:
Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · liters/hour
Apparent Total Clearance of Azacitidine (CL/F) After Single and Multiple Doses of Azacitidine
liters/hourNormal RF: Azacitidine 75 mg/m^2Severe RI: Azacitidine 75 mg/m^2
Day 1151.55 ± 30.8885.76 ± 68.83
Day 5166.95 ± 27.59111.55 ± 51.75
PrimaryApparent Volume of Distribution of Azacitidine (Vz/F) After Single and Multiple Doses of Azacitidine

The apparent volume of distribution of azacitidine after a single dose (Day 1) and multiple doses (Day 5) for participants with normal renal function and severe renal impairment, calculated according to the equation: Vz/F = Apparent total clearance (CL/F) / terminal phase rate constant (λz).

Time frame:
Day 1 and Day 5: predose, 5, 15, 30, 45 minutes and 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose
Reported as:
Geometric mean · liters
Apparent Volume of Distribution of Azacitidine (Vz/F) After Single and Multiple Doses of Azacitidine
litersNormal RF: Azacitidine 75 mg/m^2Severe RI: Azacitidine 75 mg/m^2
Day 1259.44 ± 121.71120.47 ± 120.45
Day 5248.57 ± 115.10184.54 ± 104.34
PrimaryNumber of Participants With Adverse Events (AEs)

A serious adverse event is one that at any dose of the study drug or at any time during the period of observation: * Results in death; * Is life threatening; * Requires inpatient hospitalization or prolongation of existing hospitalization; * Results in persistent or significant disability/incapacity; * Is a congenital anomaly/birth defect; * Is medically important. The Investigator assessed each AE for potential causal relationship between the event and study drug. The intensity of adverse changes in physical signs or symptoms was graded from 1 to 5 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3, and according to the following: Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Life threatening (Grade 4), or Death (Grade 5).

Time frame:
Initial treatment phase: Days 1-11 for participants who received a single dose; Days 1-29 for participants who received multiple doses. Extension treatment period: From the date of first dose until 28 days after the date of last dose (up to 7 months).
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RI
Any adverse event43656144
Adverse event related to study drug2344382
Serious adverse event0041183
Serious adverse event related to study drug0001011
Grade 3 or 4 adverse event00413103
AE leading to study drug discontinuation0000042
AE leading to study drug interruption0000041
AE leading to a dose reduction0000010
AE leading to other action taken21645103
Death0000011

Adverse events

Collected over Initial treatment phase: Days 1-11 for participants who received a single dose; Days 1-29 for participants who received multiple doses. Extension treatment period: From the date of first dose until 28 days after the date of last dose (up to 7 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azacitidine 25 mg/m^2—0/5 (0%)4/5 (80%)
Azacitidine 50 mg/m^2—0/5 (0%)3/5 (60%)
Azacitidine 75 mg/m^2—4/6 (66.7%)5/6 (83.3%)
Azacitidine 100 mg/m^2—1/5 (20%)5/5 (100%)
Severe RI: Azacitidine 75 mg/m^2—1/6 (16.7%)6/6 (100%)
Extension Phase: Normal RF—8/14 (57.1%)9/14 (64.3%)
Extension Phase: Severe RI—3/4 (75%)4/4 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RI
DyspneaRespiratory, thoracic and mediastinal disorders0/50/50/60/50/60/142/4
NauseaGastrointestinal disorders0/50/52/60/50/61/140/4
VomitingGastrointestinal disorders0/50/52/60/50/60/141/4
Small intestinal obstructionGastrointestinal disorders0/50/51/60/50/61/141/4
FatigueGeneral disorders0/50/50/60/50/60/141/4
Hemoglobin decreasedInvestigations0/50/50/60/50/60/141/4
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/50/50/60/50/61/141/4
HyponatremiaMetabolism and nutrition disorders0/50/50/61/50/61/140/4
Back painMusculoskeletal and connective tissue disorders0/50/50/61/50/60/140/4
AnemiaBlood and lymphatic system disorders0/50/51/60/50/60/140/4
Most frequent other events
Showing 10 of 81
Most frequent other events
EventAzacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RI
FatigueGeneral disorders0/50/52/63/52/63/141/4
NeutropeniaBlood and lymphatic system disorders0/50/50/60/52/62/142/4
NauseaGastrointestinal disorders0/50/51/62/50/62/142/4
VomitingGastrointestinal disorders0/50/53/60/50/60/141/4
Injection site painGeneral disorders0/52/51/61/52/60/140/4
AnaemiaBlood and lymphatic system disorders0/50/51/60/52/61/141/4
Injection site reactionGeneral disorders0/50/52/60/50/60/140/4
Decreased appetiteMetabolism and nutrition disorders0/50/52/61/50/62/140/4
ConstipationGastrointestinal disorders1/50/51/60/50/64/141/4
LeukopeniaBlood and lymphatic system disorders0/50/50/60/50/62/141/4

Baseline characteristics

Safety population. The total number of participants in the study was 27; 18 continued treatment in the extension phase.

Age, Continuous
Age, Continuous(years)Azacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RITotal
Initial Treatment Period67.6 ± 3.7864.6 ± 9.6353.5 ± 10.1957.0 ± 12.0274.5 ± 12.58NA ± NANA ± NA63.5 ± 12.32
Extension Treatment PeriodNA ± NANA ± NANA ± NANA ± NANA ± NA60.6 ± 9.5268.8 ± 11.062.4 ± 10.15
Sex/Gender, Customized
Sex/Gender, Customized(participants)Azacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RITotal
Female333430016
Male223130011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Azacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RITotal
Black12122008
White435340019
Region of Enrollment
Region of Enrollment(participants)Azacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RITotal
United States556560027
Gender of Extension Period Participants
Gender of Extension Period Participants(participants)Azacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RITotal
Female000008210
Male00000628
Race: Extension Phase
Race: Extension Phase(participants)Azacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RITotal
Black00000505
White000009413
Eastern Cooperative Oncology Group (ECOG) Performance Status: Initial Treatment Phase
Eastern Cooperative Oncology Group (ECOG) Performance Status: Initial Treatment Phase(participants)Azacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RITotal
022102007
1334530018
200101002
Eastern Cooperative Oncology Group (ECOG) Performance Status: Extension Phase
Eastern Cooperative Oncology Group (ECOG) Performance Status: Extension Phase(participants)Azacitidine 25 mg/m^2Azacitidine 50 mg/m^2Azacitidine 75 mg/m^2Azacitidine 100 mg/m^2Severe RI: Azacitidine 75 mg/m^2Extension Phase: Normal RFExtension Phase: Severe RITotal
000000213
10000011314
200000101

3 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • Sutter East Bay Hospitals
    Berkeley, California 94704, United States
  • Palm Springs Research Institute
    Hialeah, Florida 33012, United States
  • MCG Cancer Center
    Augusta, Georgia 30912, United States
  • Joliet Oncology-Hematology Associates, Ltd.
    Joliet, Illinois 60435, United States
  • University of Kentucky-Markey Cancer Center Clinical Research Organization
    Lexington, Kentucky 40536, United States
  • Nevada Cancer Institute
    Las Vegas, Nevada 89135, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Mid Dakota Clinical P.C. - Cancer Treatment and Research Center
    Bismarck, North Dakota 58501, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Pharma Resource
    East Providence, Rhode Island 02915, United States
  • Cancer Therapy and Research Center
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Wehmeyer J, Zaiss M, Losem C, Schmitz S, Niemeier B, Harde J, Hannig CV, Harich HD, Muller J, Klausmann M, Tessen HW, Potthoff K. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study). Eur J Haematol. 2018 Dec;101(6):766-773. doi: 10.1111/ejh.13160. Epub 2018 Oct 25. PubMed 30091166 ↗
  • Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlagel U, Mutherig A, Fransecky L, Noppeney R, Bug G, Gotze KS, Kramer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stolzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hanel M, Duhrsen U, Schetelig J, Rollig C, Kramer M, Ehninger G, Bornhauser M, Thiede C. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12. PubMed 30442503 ↗
  • Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, Jordan CT, Smith C, Pollyea DA. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Leuk Res. 2019 Jun;81:43-49. doi: 10.1016/j.leukres.2019.04.005. Epub 2019 Apr 13. PubMed 31009835 ↗
  • Laille E, et al. A 2-Part Phase I Study in Patients with Solid or Hematologic Malignancies: Dose Proportionality of Subcutaneous (SC) Azacitidine (AZA) and Pharmacokinetics of SC AZA in Patients with Severe Renal Impairment . Presented at American Society of Hematology 2011, December 10-13, 2011, San Diego, CA. Abstract No. 3480.
  • Du X, Lai YY, Xiao Z, Liu T, Hu Y, Sun A, Li X, Shen ZX, Jin J, Yu L, Laille E, Dong Q, Songer S, Beach CL. Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. Asia Pac J Clin Oncol. 2018 Jun;14(3):270-278. doi: 10.1111/ajco.12835. Epub 2017 Dec 28. PubMed 29282890 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2008 to primary completion in Jul 2012, 44 months.

Results were first posted in Oct 2013, 1 year 3 months after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 44 months is close to that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 4, 2008
StartActual
Nov 1, 2008
Primary completionActual
Jul 1, 2012
CompletionActual
Jul 1, 2012
Results first posted
Oct 17, 2013
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00652626
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 4, 2008
Start date
Nov 1, 2008
Primary completion
Jul 1, 2012
Completion
Jul 1, 2012
Results posted
Oct 17, 2013
Last update
Nov 19, 2019

Study contacts

Jay Backstrom, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion